|Bid||125.54 x 800|
|Ask||125.57 x 800|
|Day's Range||124.37 - 126.90|
|52 Week Range||106.11 - 151.24|
|Beta (3Y Monthly)||1.54|
|PE Ratio (TTM)||722.54|
|Earnings Date||May 22, 2019 - May 28, 2019|
|Forward Dividend & Yield||1.56 (1.31%)|
|1y Target Est||140.77|
Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of McKesson Corporation and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers. This publication does not announce a credit rating action and is not an indication of whether or not a credit rating action is likely in the near future.
The founder and chairman of Charles Schwab said he's "not sure" whether the company's headquarters will remain in San Francisco.
McKesson Corp provides medicines, pharmaceutical supplies, information and care management products and services across the healthcare industry. It operates with two segments namely McKesson Distribution Solutions and McKesson Technology Solutions. The dividend yield of McKesson Corp stocks is 1.20%.
The bank has almost every line of business in the Bay Area, including wealth management as well as lending to small and mid-sized companies and real estate investors.
IRVING, Texas-- -- Fourth-quarter fiscal 2019 revenues of $52.4 billion and full-year fiscal 2019 revenues of $214.3 billion, a full-year increase of 3%. Fourth-quarter GAAP loss per diluted share from continuing operations of $ and full-year GAAP earnings per diluted share from continuing operations of $0.17. Fourth-quarter Adjusted Earnings per diluted share of $3.69, up 6% from a year ago. Full-year ...
The company also said it had renewed a distribution agreement with its largest client, CVS Health Inc, through 2023. "McKesson reported mixed end to its FY19, but in this environment that is likely to be enough especially as guidance met expectations," an Evercore ISI note said. The mid-point of the company's 2020 adjusted profit outlook of between $13.85 and $14.45 per share was a cent above the average analyst estimate, according to IBES data from Refinitiv.
McKesson's (MCK) Q4 results benefit from higher revenues, gross margin expansion and solid show by U.S. Pharmaceutical and Specialty Solutions.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Today we will run through one way of estimating the intrinsic value of McKesson Corporation (NYSE:MCK...
McKesson (MCK) delivered earnings and revenue surprises of 0.82% and -1.73%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Shares of McKesson Corp. rose 1.3% in premarket trade Wednesday after the company reported fourth-quarter earnings that beat Wall Street expectations, though it missed on revenue. McKesson posted a loss of $796 million, or a loss of $4.17 per share, compared with a loss of $1.15 billion, or $5.58 per share, in the year-earlier quarter. Adjusted EPS came in at $3.69, above the FactSet consensus of $3.66. Revenue rose to $52.43 billion from $51.63 billion a year ago, but missed the FactSet consensus of $53.17 billion. The company said it expects full-year adjusted earnings per share of between $13.85 and $14.45. Shares of McKesson have gained 13.8% so far this year, while the S&P 500 has gained 15%.
On a per-share basis, the San Francisco-based company said it had a loss of $4.17. Earnings, adjusted for non-recurring costs and restructuring costs, were $3.69 per share. The results beat Wall Street ...
U.S. drug distributor McKesson Corp reported a smaller fourth-quarter loss on Wednesday, as its surgical distribution business was boosted by the company's recent acquisition of Medical Specialties Distributors ...
is expected to report quarterly earnings of $3.66 a share on sales of $53.2 billion after the market closes on Wednesday, based on a FactSet survey of 14 analysts. McKesson is currently trading at a price-to-forward-earnings ratio of 8.7 based on the 12-month estimates of 17 analysts surveyed by FactSet. McKesson is one of the companies Real Money's Paul Price is watching closely.
McKesson Corp NYSE:MCKView full report here! Summary * Perception of the company's creditworthiness is negative * ETFs holding this stock are seeing positive inflows but are weakening * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is extremely low for MCK with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting MCK. Money flowETF/Index ownership | NegativeETF activity is negative and may be weakening. The net inflows of $2.88 billion over the last one-month into ETFs that hold MCK are among the lowest of the last year and appear to be slowing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swap | NegativeThe current level displays a negative indicator. MCK credit default swap spreads are near their highest levels for the past 1 year, which indicates the market's more negative perception of the company's credit worthiness.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Anticipated growth across core business unit and solid show by Medical Surgical and European Pharmaceutical Solutions is likely to aid McKesson's (MCK) Q4 earnings. However, rising costs might be a dampener.
CHARLESTON, W.Va. (AP) — West Virginia has reached a $37 million settlement with the drug distributor McKesson in a lawsuit accusing the company of shipping millions of suspicious painkiller orders to the state as it was being ravaged by the opioid epidemic.